Synovial Sarcoma
Conditions
Keywords
Adoptive cell transfer, Cell therapy, Immunotherapy, NY-ESO-1, T cell receptor gene therapy, Synovial sarcoma
Brief summary
The purpose of this study is to evaluate the safety and the efficacy of TBI-1301 for NY-ESO-1 expressing synovial sarcoma when administered following cyclophosphamide pre-treatment.
Detailed description
Following pre-treatment with cyclophosphamide, NY-ESO-1-specific T cell receptor (TCR) gene transduced T lymphocytes are transferred to human leukocyte antigen (HLA)-A\*02:01 or HLA-A\*02:06 positive patients with synovial sarcoma expressing NY-ESO-1, which are surgically unresectable and refractory to anthracycline therapy. The primary objective is to evaluate the safety in the phase 1 and the efficacy in the phase 2.
Interventions
BIOLOGICALTBI-1301
Split dose of TBI-1301 is administered intravenously for 2 days following cyclophosphamide pre-treatment.
DRUGCyclophosphamide
Cyclophosphamide (750mg/m2/day x 2 days Intravenous (IV)) is administered as pre-treatment medication of TBI-1301.
Sponsors
Takara Bio Inc.
Study design
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Histologically confirmed synovial sarcoma 2. Surgically unresectable tumor 3. Progressing or recurrent synovial sarcoma which has been treated with 1-4 regimens of systemic chemotherapies including anthracycline 4. HLA-A\*02:01 or HLA-A\*02:06 positive 5. Tumor that express NY-ESO-1 by immunohistochemistry 6. ≥ 18 years of age 7. Measurable lesions that are evaluable by the RECIST ver1.1 8. ECOG Performance Status of 0, 1 or 2 9. No treatment such as chemotherapy and be expected to recover fully from the previous treatment at the time of the lymphocytes collection for manufacturing 10. Life expectancy ≥ 16 weeks after consent 11. No severe damage on the major organs (bone marrow, heart, lung, liver, kidney, etc) and meet the following lab value criteria; Total bilirubin ≤ 1.5 x upper limit of normal (ULN); AST(GOT), ALT(GPT) \< 3.0 x ULN; Creatinine \< 1.5 x ULN; 2,500/μL \< WBC ≤ULN; Hemoglobin ≥ 8.0g/dL; Platelets ≥ 75,000/μL 12. Patients must be able to understand the study contents and to give a written consent at his/her free will. Additionally, if patients are below 20 years of age, proxies must be able to give a written consent.
Exclusion criteria
1. Patients with the following conditions are excluded from the study; Unstable angina, cardiac infarction, or heart failure; Uncontrolled diabetes or hypertension; Active infection; Obvious interstitial pneumonia or lung fibrosis by chest X-ray; Active autoimmune disease requiring steroids or immunosuppressive therapy. 2. Active metastatic tumor cell invasion into CNS 3. Active multiple cancer 4. Positive for HBs antigen or HBV-DNA observed in serum 5. Positive for HCV antibody and HCV-RNA observed in serum 6. Positive for antibodies against HIV or HTLV-1 7. Left Ventricular Ejection Fraction (LVEF) ≤ 50% 8. History of serious hypersensitivity reactions to bovine or murine derived substances. 9. History of hypersensitivity reaction to ingredients or excipients of investigational drugs used in this study 10. History of hypersensitivity reaction to antibiotics used in manufacturing for the investigational drug used in this study. 11. Pregnant females, lactating females (except when they cease and do not resume lactation) or female and male patients who cannot agree to practice the adequate birth control from the consent to 6 months after infusion of the investigational drug. 12. Clinically significant systemic illness that in the judgment of the PI or sub-investigator would compromise the patient's ability to tolerate protocol therapy or significantly increase the risk of complications.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| (Phase I) Adverse event, mortality, severe adverse event, discontinuation due to adverse event, laboratory test values | 52 weeks | Confirm the toxicity profile, which is measured by the degree of grade and seriousness, duration, causality, classification, etc. of the adverse events. |
| (Phase I) Appearance of replication competent retrovirus (RCR) by PCR | 52 weeks | Confirm that no replication competent retrovirus observed. |
| (Phase I) Appearance of clonality by linear amplification mediated (LAM)-PCR | 52 weeks | Confirm that no clonality is observed. |
| (Phase I) Blood kinetics of TBI-1301 by realtime-PCR | 52 weeks | Evaluate persistence and expansion of transferred TBI-1301. |
| (Phase II) Overall response rate | 52 weeks | Evaluate response rate by measuring response using RECIST v1.1 and irRECIST |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| (Phase II) Appearance of RCR | 52 weeks | Confirm that no replication competent retrovirus observed. |
| (Phase I) Objective response rate | 52 weeks | Evaluate response rate by measuring response using RECIST v1.1 and irRECIST |
| (Phase II) Blood kinetics of TBI-1301 by realtime-PCR | 52 weeks | Evaluate persistence and expansion of transferred TBI-1301. |
| (Phase II) Appearance of clonality (LAM-PCR) | 52 weeks | Confirm that no clonality is observed. |
| (Phase I/II) Progression free rate | 12 weeks | Evaluate progression free rate by measuring response using RECIST v1.1 and irRECIST |
| (Phase I/II) Progression free survival | 52 weeks | Evaluate progression free survival |
| (Phase I/II) Overall survival | 52 weeks | Evaluate overall survival |
| (Phase II) Adverse event, mortality, severe adverse event, discontinuation due to adverse event, laboratory test values | 52 weeks | Confirm the toxicity profile, which is measured by the degree of grade and seriousness, duration, causality, classification, etc. of the adverse events. |
Countries
Japan
Outcome results
None listed